FDA Approves Adjuvant Nivolumab for Resected, Stage IIB/C Melanoma
Recommended
FDA Approves Adjuvant Nivolumab for Resected, Stage IIB/C Melanoma
On October 13, 2023, The US Food and Drug Administration (FDA) approved nivolumab in the adjuvant setting for patients 12 years and older with completely resected stage IIB/C melanoma.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->